Is radiation therapy required for patients with intermediate-risk rectal cancer?

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 8, 2007, Pages

  Mamon, Harvey ^a   Willett, Christopher G ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Combined modality therapy; Local recurrence; Radiation theraphy; Rectal neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; SEMUSTINE; VINCRISTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DYSURIA; ENTERITIS; FATIGUE; FECES INCONTINENCE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INTESTINE OBSTRUCTION; LOOSE FECES; MORBIDITY; NEUROGENIC BLADDER; PATIENT SELECTION; PREOPERATIVE RADIOTHERAPY; PROGNOSIS; QUALITY OF LIFE; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CANCER; RECTUM HEMORRHAGE; RECTUM SURGERY; RISK FACTOR; SEXUAL DYSFUNCTION; SKIN IRRITATION; TREATMENT FAILURE; TREATMENT OUTCOME;

BRACHYTHERAPY; HUMANS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; RISK ASSESSMENT;

EID: 34948910715     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Minsky BD, Mies C, Recht A, Rich TA, Chaffey JT. Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer. 1988;61:1408-1416.
2. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358:1291-1304.
3. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284: 1008-1015.
4. Improved survival with preoperative radiotherapy in resectable rectal cancer: Swedish Rectal Cancer Trial [published erratum appears in N Engl J Med. 1997;336:1539]. N Engl J Med. 1997;336:980-987.
5. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med. 1985;312:1465-1472.
6. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709-715.
7. Tveit KM, Guldvog I, Hagen S, et al. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer: Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg. 1997;84:1130-1135.
8. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80:21-29.
9. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264(11):1444-1450.
10. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted- infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331:502-507.
11. Lee JH, Lee JH, Ahn JH, et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol. 2002;20: 1751-1758.
12. Gunderson LL, Dosoretz DE, Hedberg SE, et al. Low-dose preoperative irradiation, surgery, and elective postoperative radiation therapy for resectable rectum and rectosigmoid carcinoma. Cancer. 1983;52:446-451.
13. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum. 1999;42:167-173.
14. Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control: final report of intergroup 0114. J Clin Oncol. 2002;20:1744-1750.
15. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004;22:1785-1796.
16. Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000;92:388-396.
17. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002;54:386-396.
18. Glimelius B, Isacsson U, Jung B, Pahlman L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment. Int J Radiat Oncol Biol Phys. 1997;37:281-287.
19. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644-5650.
20. Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg. 1990;211:187-195.
21. Roh M, Petrelli N. Wieand S, et al. Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). Proc Am Soc Clin Oncol. 2001;20:123a. Abstract 490.
22. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.
23. Enker WE. Potency, cure, and local control in the operative treatment of rectal cancer. Arch Surg. 1992;127:1396-1401; discussion 1402.
24. Heald RJ, Karanjia ND. Results of radical surgery for rectal cancer. World J Surg. 1992;16:848-857.
25. Havenga K, Enker WE, Norstein J, et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol. 1999;25:368-374.
26. Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181: 335-346.
27. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638-646.
28. van den Brink M, Stiggelbout AM, van den Hour WB, et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol. 2004;22:3958-3964.
29. Van Den Brink M, Van Den Hour WB, Stiggelbout AM, et al. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group. J Clin Oncol. 2004;22:244-253.
30. Guadagnolo B, Maroon H. Long-term adverse effects of pre-operative radiation therapy for rectal cancer: the Swedish Rectal Cancer Trial. Am J Oncol Rev. 2006;5:1-3.
31. Kollmorgen CF, Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Illstrup DM. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg. 1994;220:676-682.
32. Mak AC, Rich TA, Schultheiss TE, Kavanagh B, Ota DM, Romsdahl MM. Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid. Int J Radiat Oncol Biol Phys. 1994;28:597-603.
33. Gallagher MJ, Brereton HD, Rostock RA, et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys. 1986;12:1565-1573.
34. Letschert JG, Lebesque JV Aleman BM, et al. The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma. Radiother Oncol. 1994;32:116-123.
35. Minsky BD, Conti JA, Huang Y, Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol. 1995;13:1409-1416.
36. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215-1223.
37. Dahlberg M, Glimelius B, Graf W, Pahlman L. Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum. 1998;41:543-549; discussion 549-551.
38. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse effects of pre-operative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005;23:8697-8705.
39. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol. 2005;23:6126-6131.
40. Madoff RD. Chemoradiotherapy for rectal cancer-when, why, and how? N Engl J Med. 2004;351:1790-1792.
41. Frykholm GJ, Pahlman L, Glimelius B. Treatment of local recurrences of rectal carcinoma. Radiother Oncol Mar. 1995;34(3):185-194.
42. Holm T, Cedermark B, Rutqvist LE. Local recurrence of rectal adenocarcinoma after 'curative' surgery with and without preoperative radiotherapy. Br J Surg. 1994;81:452-455.
43. Wiggers T, de Vries MR, Veeze-Kuypers B. Surgery for local recurrence of rectal carcinoma. Dis Colon Rectum. 1996;39:323-328.
44. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: histopathological study of lateral tumour spread and surgical excision. Lancet. 1986;2:996-999.
45. Adam IJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994;344:707-711.
46. Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde Q, van Krieken JH. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002;26:350-357.
47. Stocchi L, Nelson H, Sargent DJ, et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol. 2001;19:3895-3902.
48. Machiels JP, Aydin S, Bonny MA, Hammouch F, Sempoux C. What is the best way to predict disease-free survival after preoperative radiochemotherapy for rectal cancer patients: tumor regression grading, nodal status, or circumferential resection margin invasion? J Clin Oncol. 2006;24:1319; author reply 1320-1311.
49. Rodel C, Marius P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-8696.
50. Mawdsley S, Glynne-Jones R, Grainger J, et al. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict fbr 3-year disease-free survival? Int J Radiat Oncol Biol. Phys. 2005;63:745-752.
51. Wibe A, Syse A, Andersen E, Tretli S, Myrvold HE, Soreide O. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum. 2004;47:48-58.
52. Greene FL, Stewart AK, Norton HJ. New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol. 2004;22:1778-1784.
53. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001;19: 157-163.
54. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124:979-994.
55. Goldstein NS. Lymph node recoveries fiom 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol. 2002;26(2):179-189.
56. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24: 1031-1036.
57. Villafranca E, Okruzhnov Y, Dominguez MA et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol, 2001;19:1779-1786.
58. Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 2005; 23:1826-1838.
59. Marijnen CA, Nagtegaal ID, Mulder-Stapel AA, et al. High intrinsic apoptosis, but not radiation-induced apoptosis, predicts better survival in rectal carcinoma patients. Int J Radiat Oncol Biol Phys. 2003;57:434-443.
60. de Bruin EC, van de Velde CJ, van de Pas S, et al. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res. 2006;12: 6432-6436.
61. Pijl ME, Chaoui AS, Wahl RL, van Oostayen JA. Radiology of colorectal cancer. Eur J Cancer. 2002;38:887-898.
62. Sebag-Montefiore D, Steele R, Quirke P, et al. Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. J Clin Oncol. 2006;24(18S): Abstract 3511.
63. Gerard JB, Chapet O, Nemoz C, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol. 2003;21: 1119-1124.
64. Ryan DP, Niedzwiecki D, Hollis D, et al. Phase I/II study of preoperative oxaliplatin, fluarouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol. 2006;24:2557-2562.
65. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol. 2003;21:3098-3104.
66. Rodel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25:110-117.
67. Mitchell EP. Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer. Oncology (Miston Park). 2000;14(12 suppl 14):56-59.
68. Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006;24:650-655.
69. Glynne-Jones R, Falk S, Maughan TS, Meadows HM, Sebag-Montefiore D. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer. F2007;96:551-558.
70. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147.